Year: 2023

Global Healthcare Analytics Market Size USD 249.87 Billion by 2032 | Emergen Research

Written by Customer Service on November 8, 2023. Posted in Mergers And Acquisitions.

Rising adoption of analytics for marketing and sales purposes in the healthcare industry and rising beneficial initiatives by governments are driving the healthcare analytics market. Vancouver, Nov. 08, 2023 (GLOBE NEWSWIRE) — The global healthcare analytics market is estimated to reach USD 249.87 Billion by 2032, according to a current analysis by Emergen Research. During the forecast period, the global healthcare analytics market is likely to expand significantly, due to the rising adoption of analytics for marketing and sales purposes in the healthcare industry. Rising beneficial initiatives by governments such as inclusion of electronic health records (EHRs) in hospitals and clinics are expected to fuel the global healthcare analytics market during the forecast period. Moreover, growing awareness about evidence-based and personalized...

Semantix Announces 3Q 2023 Financial Results

Written by Customer Service on November 8, 2023. Posted in Earnings Releases And Operating Results.

Gross margin improved 14 p.p. to 62% and Proprietary SaaS Revenue increased 41% in the 3Q23 compared to 3Q22 SÃO PAULO, Brazil, Nov. 08, 2023 (GLOBE NEWSWIRE) — Semantix, Inc. (NASDAQ: STIX), a leading Latin American enterprise AI platform and applications provider, today announced its financial results for the third quarter ended September 30, 2023. “We’re excited to report another quarter of substantial year-over-year growth in our proprietary SaaS offerings, primarily driven by the success of our AI applications, especially within the specific industry sectors we’ve prioritized. We continue to see promising growth opportunities in these areas,” shared Leonardo Santos, CEO and Founder of Semantix. “This positive shift in our revenue mix, alongside strategic decisions aimed at ensuring our business’s...

Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences

Written by Customer Service on November 8, 2023. Posted in Public Companies.

BOSTON, Nov. 08, 2023 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that members of the Atea management team will participate in and present a business update at the following investor conferences in November.Jefferies London Healthcare Conference, Company Presentation on Wednesday, November 15, 2023 at 11:00 a.m. GMT / 7:00 a.m. ET6th Annual Evercore ISI HealthCONx Conference, Fireside Chat on Wednesday, November 29, 2023 at 3:00 p.m. ETLive webcasts of the presentations will be available on the Company’s website at https://ir.ateapharma.com/. An archived webcast will be available on Atea Pharmaceuticals’ website for at least 90 days following...

PolyPid Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Written by Customer Service on November 8, 2023. Posted in Earnings Releases And Operating Results.

Total of 20 Centers Currently Open with Approximately 40 Expected by End of 2023 in SHIELD II Phase 3 Trial Evaluating D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Completed Production and Release of Three Process Validation Batches of D-PLEX100 Successful Completion of Good Manufacturing Practice Audit of Company’s Manufacturing Facility Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Nov. 08, 2023 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today provided a corporate update and reported financial results for the three and nine months ended September 30, 2023. Recent Corporate Highlights:A total of 20 centers are currently open in the ongoing SHIELD II Phase 3 trial that...

1stDibs Reports Third Quarter 2023 Financial Results

Written by Customer Service on November 8, 2023. Posted in Earnings Releases And Operating Results.

NEW YORK, Nov. 08, 2023 (GLOBE NEWSWIRE) — 1stdibs.com, Inc. (NASDAQ: DIBS), a leading online marketplace for luxury design products (“1stDibs” or the “Company”), today reported financial results for its third quarter ended September 30, 2023. Third Quarter 2023 Financial HighlightsNet revenue was $20.7 million, a decrease of 9% year-over-year. Gross profit was $15.2 million, a decrease of 2% year-over-year. Gross margin was 73.3%, compared to 68.0% in the third quarter 2022. GAAP net loss was $3.3 million compared to a net loss of $9.0 million in the third quarter 2022. Non-GAAP Adjusted EBITDA and Adjusted EBITDA Margin was $(1.8) million and (8.7)%, respectively, compared to $(5.5) million and (24.0)%, respectively, in the third quarter 2022. Cash, cash equivalents and short-term investments totaled...

Royalty Pharma Reports Third Quarter 2023 Results

Written by Customer Service on November 8, 2023. Posted in Earnings Releases And Operating Results.

Net cash provided by operating activities (GAAP) of $574 million and Adjusted Cash Receipts(1) (non-GAAP) of $637 million Announced transactions of up to $3.8 billion year-to-date, including $2.1 billion in upfront payments Raising 2023 guidance: Adjusted Cash Receipts(1) (non-GAAP) expected to be $2,950 to $3,000 millionNEW YORK, Nov. 08, 2023 (GLOBE NEWSWIRE) — Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2023 and raised full-year 2023 guidance for Adjusted Cash Receipts(1) (a non-GAAP financial measure). “We delivered another quarter of impressive financial performance, as well as substantial deal activity,” said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer. “We were thrilled to acquire royalties on three innovative therapies, increasing our announced...

Lexicon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

Written by Customer Service on November 8, 2023. Posted in Earnings Releases And Operating Results.

Commercial launch of INPEFA® (sotagliflozin) as a differentiated, new treatment option for heart failure patients shows meaningful progress in Q3 with increasing demand across the cardiology community Significant formulary inclusions effective in Q4 opening the opportunity for further commercial acceleration into 2024 and beyond LX9211 moving into late-stage development for the treatment of diabetic peripheral neuropathic pain Conference Call and Webcast at 8:00 am Eastern Time THE WOODLANDS, Texas, Nov. 08, 2023 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended September 30th, 2023 and provided an update on key corporate milestones. “We achieved important milestones this quarter in commercially launching INPEFA (sotagliflozin) in the U.S. for the treatment...

Steve Madden Announces Third Quarter 2023 Results

Written by Customer Service on November 8, 2023. Posted in Earnings Releases And Operating Results.

LONG ISLAND CITY, N.Y., Nov. 08, 2023 (GLOBE NEWSWIRE) — Steven Madden, Ltd. (Nasdaq: SHOO), a leading designer and marketer of fashion-forward footwear, accessories and apparel, today announced financial results for the third quarter ended September 30, 2023. Amounts referred to as “Adjusted” are non-GAAP measures that exclude the items defined as “Non-GAAP Adjustments” in the “Non-GAAP Reconciliation” section. Third Quarter 2023 ResultsRevenue decreased 0.7% to $552.7 million compared to $556.6 million in the same period of 2022. Gross profit as a percentage of revenue was 42.1% compared to 41.2% in the same period of 2022. Operating expenses as a percentage of revenue were 27.1%, which is the same percentage as in the same period of 2022. Adjusted operating expenses as a percentage of revenue were 27.0%, also the same percentage...

CTG IT Solutions and Services Segments Gross Margin Improved 40 Basis Points to 29.5% in Third Quarter 2023

Written by Customer Service on November 8, 2023. Posted in Earnings Releases And Operating Results.

Cegeka and CTG work toward Completion of Regulatory Requirements to Complete AcquisitionCegeka and CTG signed an agreement on August 9, 2023, for Cegeka to purchase CTG for $10.50 per share in a cash transaction valued at approximately $170 million. IT Solutions and Services segments represent 87% of total revenue in the third quarter, CTG’s highest level to date. Revenue of $71.3 million reflected intentional disengagement of $11.8 million from non-strategic technology services business. Gross margin improved to 27.3%, or 300 basis points from the prior year. GAAP operating margin was (0.8)% in third quarter; non-GAAP operating margin was 3.7% Net loss was ($0.9) million, with a net margin of (1.2)%; adjusted EBITDA was $3.1 million, with a margin of 4.3%BUFFALO, N.Y., Nov. 08, 2023 (GLOBE NEWSWIRE) — CTG (Nasdaq: CTG) (“Company”),...

ANI Pharmaceuticals Reports Record Third Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance

Written by Customer Service on November 8, 2023. Posted in Earnings Releases And Operating Results.

Third Quarter 2023 Financial Results — Record quarterly net revenues of $131.8 million, representing year-over-year growth of 57.3%; net income available to common shareholders of $9.5 million and diluted GAAP income per share of $0.45 — — Record quarterly adjusted non-GAAP EBITDA of $36.5 million representing year-over-year growth of 98.3%; adjusted non-GAAP diluted earnings per share of $1.27 — — Lead Rare Disease asset, Purified Cortrophin® Gel (Repository Corticotrophin Injection USP) 80 U/ml (Cortrophin Gel) reported net sales of $29.7 million, a year-over-year increase of 135.9% — — Generics, Established Brands and Other reported net sales of $102.1 million, representing year-over-year growth of 43.4% — Full Year 2023 Guidance — Company raises guidance: net revenue to $468 million...

Year: 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals